Rueda de prensa de Gregory Winter y Richard Lerner.
Reciben el premio príncipe de asturias de 2012 por sus importantes descubrimientos para el desarrollo de los anticuerpos monoclonales "humanizados" y su uso en el tratamiento de patologías.
Research and publish the best content.
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Already have an account: Login
Immunopathology & Immunotherapy
10.4K views |
+0 today
Latest advances in immunopathology diagnosis and treatment
Curated by
Alfredo Corell
 Your new post is loading...
Your new post is loading...
Scoop.it!
Prof. G.V. Scagliotti and Prof. Tony Mok
CONTENTS: -Introduction -LUX-Lung 3: Improved Quality of Life, as Expected -PSF v OS: why the disparity? -Reversible and Irreversible TKI -Crizotinib: Standard of Care for ALK-Positive Disease -Unusual Toxicity Profile of Crizotinib -Crizotinib of Benefit to ROS1-Positive Patients -A Durg for Every Mutation 
Scoop.it!
Conclusions Anti–PD-1 antibody produced objective responses in approximately one in four to one in five patients with non–small-cell lung cancer, melanoma, or renal-cell cancer; the adverse-event profile does not appear to preclude its use. Preliminary data suggest a relationship between PD-L1 expression on tumor cells and objective response. (Funded by Bristol-Myers Squibb and others; ClinicalTrials.gov number, NCT00730639.)
Link to NEJM:
|
Scoop.it!
El Ministerio de Sanidad ha aprobado el uso y la financiación pública del ipilimumab, una novedosa inmunoterapia contra el melanoma metastásico. Según los ensayos del laboratorio que lo ha desarrollado, BMS, este fármaco prolonga la supervivencia de los afectados de una media de seis o nueve meses a hasta cinco años.
Scoop.it!
Louis M. Weiner,Joseph C. Murray,Casey W. Shuptrine By targeting surface antigens expressed on tumor cells, monoclonal antibodies have demonstrated efficacy as cancer therapeutics. Recent successful antibody-based strategies have focused on enhancing antitumor immune responses by targeting immune cells, irrespective of tumor antigens. We discuss these innovative strategies and propose how they will impact the future of antibody-based cancer therapy. http://dx.doi.org/10.1016/j.cell.2012.02.034, How to Cite or Link Using DOI
|
